Collectively, these results suggested that the expression of PD-L1 and CD8+ T cell infiltration, together with a high-frameshift neoantigen load associated with the up-regulation of gene expression signatures related to antigen presentation and costimulatory signaling, might confer a durable clinical benefit of ICI therapy in SCLC. The gene discussed is CD8A; the disease is small cell lung carcinoma.